





Y. Cottin¹, P. Blin², J. Bénichou^{3,4}, C. Dureau-Pournin², A. Abouelfath², R. Lassalle², C. Droz-Perroteau², P. Mismetti⁵, N. Moore^{2,4} ¹CHU, Dijon, France – ²Bordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, France – ³CHU, Rouen, France – ⁴INSERM U1219, Bordeaux, France – ⁵CHU, Saint-Etienne, France

- Purpose **Populations** better benefit-risk than vitamin-K antagonists (VKA) for non-valvular atrial fibrillation (NVAF) in clinical trials, but real-life benefits and risks in the elderly are > Of 371,539 new users of dabigatran, rivaroxaban or VKA in 2013 in France: still uncertain. • 9,257 patients aged \geq 80 years were treated with dabigatran, • 44,653 with VKA for NVAF. database, the one-year risk of major events in new elderly users of dabigatran or > For dabigatran versus VKA, 8,569 patients were matched per treatment group VKA for NVAF. (93% of dabigatran group). > Patient characteristics and hdPS distribution showed differences between 110mg twice daily due to the higher risk for bleeding in this population. treatment groups, and were normalized after matching (Table 1, Figure 1). After matching, standardized differences were < 10% for all variables, even \leq 2% for Methods most variables (Figure 2). Table 1. Main patients characteristics in all NVAF populations Study design Dabigatran ≥ 80 years n = 9,257 Male, n (%) 3794 (41.0) 85.1 (3.9) Age at index date (in years), mean (± SD) Age at index date (in categories), n (%) (0.0) < 80 years ≥ 80 years 9257 (100.0) Stroke risk factors¹ (score), n (%) Congestive heart failure 2151 (23.2) Hypertension 4451 (48.1) Gender, date of birth, area of residence, date of death; 9257 (100.0) Age \geq 75 years (18.3) **Diabetes mellitus** 1692 Long-term disease registration with associated ICD-10 codes for full insurance Stroke or transient ischemic attack (TIA) history (14.9) 1383 coverage (with start and end dates); Vascular disease history 1313 (14.2) Hospital discharge summaries with ICD-10 codes for diagnosis (primary, linked Age 65-74 years (0.0) (59.0) 5463 Women and associated diagnoses) for all private and public medical, obstetric and CHA_2DS_2 -VASc score \geq 2, n (%) 9257 (100.0) surgery hospitalisations, with the date and duration of hospitalisation, medical Bleeding risk factors¹ (score), n (%) procedures. 4451 (48.1) Hypertension (5.4) Abnormal renal function > NVAF population (1.0) Abnormal liver function (12.6) Stroke history 1163 Bleeding history (2.3) 214 Age > 65 years 9257 (100.0) Medication usage predisposing to bleeding (58.8) 5439 HAS-BLED score > 3, n (%) 852 (9.2) > Outcomes: during anticoagulant exposure period (on treatment) ¹ based on general characteristics of patients, long-term disease with full insurance coverage, as well as three-year • Clinical events: hospital admission with main diagnosis of clinically relevant history of hospital-discharge summary diagnosis, and drugs reimbursed bleeding (CRB), major bleeding, stroke and systemic embolism (SSE) and acute coronary syndrome (ACS); All populations **Matched populations** • Death (all-cause); - - Dabigatran >= 80 years - VKA Composite criterion: first event among CRB, SSE, ACS or death. Data analysis • 1:1 matched analysis on gender, age (±1 year), date of the first drug dispensing (±14 days), and high-dimensional propensity (hdPS)* (± 0.05). Cumulative incidence of outcomes using Kaplan-Meier estimate (death,
- > Direct oral anticoagulants (DOAC), dabigatran, rivaroxaban, and apixaban, had > The purpose of this analysis was to compare in real-life setting in a whole country > For patients aged 80 years or more, the recommended dose for dabigatran is Cohort study in the SNDS nationwide French claims database including all new users of dabigatran or VKA for NVAF aged \geq 80 years in 2013, with three-year history and one-year follow-up in the database. Data source The SNDS database contains individual pseudonymised information from 66 million persons on: Patients with long-term disease registration, hospitalisation or procedure for atrial fibrillation without valvular disease history and nor other probable indication (threeyear database history).

- composite) or cumulative incidence function (other outcomes).
- Hazard ratios (HR) [95% confidence interval] of outcomes during first prescribed anticoagulant exposure, using Cox proportional hazard risk (death, composite) or Fine and Gray models (other outcomes).

*Probability to be treated by dabigatran versus VKA using a logistic regression model with 500 variables including gender, age, stroke risk factors, bleeding risk factors

Declaration of interest: This study was funded by an unrestricted grant from

Boehringer Ingelheim France. It was designed, conducted, and analysed independently by the Bordeaux PharmacoEpi of the Bordeaux University. It was overseen by independent experts.





Benefit-risk profile of dabigatran compared with vitamin-K antagonists in elderly patients with non-valvular atrial fibrillation: results from a cohort study in the French nationwide claims database


Figure 1. hdPS distribution in all and matched populations: dabigatran ≥ 80 years versus VKA

200 -

Estimated HdPS







• Analysis of this nationwide cohort study of more than 50,000 new anticoagulant users for NVAF aged \geq 80 years shows a significantly dabigatran versus VKA in elderly patients with 16% fewer major outcomes of clinically relevant bleedings, stroke and systemic embolism





n ≥ 80 years 8,569		VKA n = 8,569
% [95%CI]	n event	% [95%CI]
3.7 [3.2; 4.2]	340	5.2 [4.7; 5.8]
2.0 [1.6; 2.4]	190	3.0 [2.6; 3.4]
2.1 [1.7; 2.5]	170	2.6 [2.2; 3.0]
1.6 [1.3; 1.9]	102	1.5 [1.2; 1.9]
8.7 [7.9; 9.5]	674	10.6 [9.8; 11.4]
4.3 [13.4; 15.3]	1130	17.1 [16.2; 18.1]

	VKA	HR [95% CI]
(n)	(n) Events (n)	HR [95% CI]
	44653 840 8569 170	0.74 [0.61 - 0.90] 0.76 [0.60 - 0.96]
	44653 1672 8569 340	0.76 [0.66 - 0.86] 0.76 [0.64 - 0.89]
	44653 936 8569 190	0.73 [0.61 - 0.88] 0.71 [0.56 - 0.89]
	44653 577 8569 102	0.86 [0.69 - 1.06] 1.01 [0.76 - 1.34]
	44653 3581 8569 674	0.76 [0.69 - 0.83] 0.84 [0.75 - 0.94]
	44653 5975 8569 1130	0.76 [0.71 - 0.82] 0.84 [0.77 - 0.92]

y better benefit-risk profile for or death.		and the second second
	1 hattar hanatit_rick pratila tar	
n or death.		
n or death.	-	
n or death.		
	I OF GASTO	